Approximately one in four patients died, deteriorated to a higher shock stage, or were transferred for a higher level of care ...

WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) announced its strategy to secure 7.5 years of U.S. exclusivity ...

Windtree Therapeutics, Inc. announced that it has received guidance from intellectual property and FDA experts regarding a potential strategy for its drug istaroxime, which targets cardiogenic shock.

The outcomes of the SHOCK trial led to a ACC/AHA class 1A recommendation for an early invasive strategy in acute MI complicated by cardiogenic ... ACC/AHA/SCAI 2005 guideline update for ...

If istaroxime is granted the new chemical entity designation from FDA, it could provide 7.5 years of U.S. exclusivity and additionally the istaroxime U.S. issued method of use patent protects until ...

avoidance of progression to SCAI Stage D or E cardiogenic shock and need for mechanical cardiac support, time to treatment failure, arrhythmia assessments, days alive and out of the hospital ...

WARRINGTON, Pa., May 06, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused ...

Cardiogenic shock happens when the heart suddenly can’t pump enough blood to meet the body’s needs. This leads to a drop in ...

Despite substantial advancements in the management of cardiogenic shock, mortality rates remain greater than 40%. Trials have ...

Other key study measurements include various measures of cardiac function, SBP changes at specified timepoints, the vasopressor-inotrope score, avoidance of progression to SCAI Stage D or E ...